Friday, June 2, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

Soligenix Wins Additional 4.3M to Advance Ricin Vaccine Manufacturing

by Global Biodefense Staff
May 5, 2016
Notable Biotechnology Contracts

Notable Biotechnology ContractsSoligenix, Inc. today announced that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised an option for RiVax™ bulk drug substance and finished drug product process scale-up and technology transfer.

The funding will support preclinical studies and manufacturing in accordance with current good manufacturing practices (cGMPs). The overall objectives of the contract are to advance the development of Soligenix’s thermostabilization technology, ThermoVax®, combined with the company’s ricin toxin vaccine, RiVax™, as a medical countermeasure to prevent the effects of ricin exposure.

See also: Thermostable Ricin Vaccine Gets Another Funding Boost

The exercised option for contract #HHSN272201400039C will provide Soligenix with an additional $4.3M in funding (total awarded to date under this contract:  $13.5M). If all contract options are exercised, the total award of up to $24.7 million will support the preclinical, manufacturing and clinical development activities necessary to advance heat stable RiVax™ with the FDA.

“The exercise of this option validates Soligenix’s success on contractual work completed to date and reflects NIAID’s ongoing commitment to advance development of viable thermostabilization technologies that can be applied to important vaccine preparations,” stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. “It also highlights the government’s commitment to identification and development of countermeasures to protect both the public and, more likely, first responders, in the event of ricin exposure.”

See also: NIAID Exercises Option on Soligenix Radiation Countermeasure

Tags: RicinThermostabilityVaccines

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics
Industry News

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023
Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC